pocketful logo light
pocketful logo light
Strides Pharma Science Ltd logo

Strides Pharma Science Ltd

NSE: STAR BSE: 532531

₹1223.10

(0.97%)

Fri, 25 Sept 2026, 09:05 pm

mtf coin illustrationMTF 5x

Strides Pharma Science Share Price Live Chart

1 Day

(0.97%)

No Result Found

Summary

  • Market Cap (in Cr)

    10223.34

  • Net Profit (in Cr)

    3597.51

  • P/B

    2.42

  • Sector P/E

    33.76

  • P/E

    1.72

  • EV/EBITDA

    1.92

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    150.84

  • ROCE

    14.28

  • Debt/Equity

    0.94

  • EPS (TTM)

    62.84

  • Dividend Yield

    0.45

  • Book Value

    337.15

  • Interest Cover

    2.67

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (2.7x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (9.1x coverage).
  • Cash flow for Strides Pharma Science is expected to increase by more than 50% in 2 years time.
  • Strides Pharma Science's earnings are expected to grow significantly at over 20% yearly.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Strides Pharma Science's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Strides Pharma Science's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Strides Pharma Science is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
  • Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters27.9127.8627.8628.3028.30
FII28.6829.5228.5128.0228.32
DII14.4513.0212.9813.3013.72
Public28.9529.5930.6430.3729.65
Government0.010.010.010.010.01

Read More

Technical Analysis

RSI

59.62

MACD

47.18

50 DMA

1065.94

200 DMA

999.77

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1253.501128.801076.901004.10952.20879.40754.70
Fibonacci1128.801081.161051.741004.10956.46927.04879.40
Camarilla1059.291047.861036.431004.101013.571002.14990.71

Pivots Level: Classic

R3

+249.40

1253.50

R2

+124.70

1128.80

R1

+72.80

1076.90

1004.10
1004.10
Pivot Point
LTP: 1184.90

S1

-51.90

952.20

S2

-124.70

879.40

S3

-249.40

754.70

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1192.77

  • 20-EMA

    1156.00

  • 30-EMA

    1129.14

  • 50-EMA

    1101.02

  • 100-EMA

    1066.63

  • 200-EMA

    1010.26

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
18 May 2026board-meetingsAccounts, Final Dividend
30 Jan 2026board-meetingsQuarterly Results
31 Oct 2025board-meetingsQuarterly Results
09 Jul 2025agm
22 Jun 2025dividendFinal Dividend - Rs. - 422 Jul 2025
22 May 2025dividend₹4.00 Dividend /Share22 Jul 2025
05 Sept 2024agm
09 Aug 2024dividendFinal Dividend - Rs. - 2.509 Sept 2024
08 Aug 2024egm
22 May 2024dividend₹2.50 Dividend /Share09 Sept 2024

Read More

Peer Comparison

Strides Pharma Science Ltd logo

Strides Pharma Science Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Strides Pharma Science Ltd About

Strides Pharma Science into the development and manufacture of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1990

Headquarters

CEO

Arun Kumar

Employees

Contact

Website icon

Website

http://www.strides.com

Email icon

Email

investors@strides.com

Phone icon

Phone

91-22-27892924/27893199

Location icon

Location

No 201 Devavrata Sector 17, Vashi, Navi Mumbai, Maharashtra, 400703

Read More

Strides Pharma Science Ltd Company History

YearHistory
2020
  • Strides Pharma Science receives USFDA approval for Prednisone tablets.
  • Strides Pharma Science receives USFDA approval for generic anti-bacterial capsules.
  • Strides arm receives EIR for US facility.
2021
  • Stelis Biopharma commissions greenfield vaccine manufacturing facility at Bengaluru.
  • Strides and TLC partner to launch black fungus drug in India.
  • Strides Pharma arm receives USFDA approval for potassium chloride oral solution.
  • Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.
2022
  • Strides receives USFDA approval for Potassium Chloride Oral Solution.
  • Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules.
  • Strides receives USFDA approval for Cyclosporine Softgel Capsules.
  • Strides receives USFDA approval for Ibuprofen Oral Suspension.
  • Strides partners with Medicines Patent Pool to commercialize generic Pfizer COVID-19 Oral Treatment across 95 markets.
2023
  • Strides receives USFDA approval for Generic Suprep Bowel Prep Kit.
  • Strides receives USFDA approval for Levetiracetam Oral Solution.
  • Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumarate tablets.
  • Strides receives USFDA approval for Icosapent Ethyl Capsules.
  • Strides receives tentative USFDA approval for Dolutegravir tablets.
2024
  • Strides receives USFDA approval for Fluoxetine Tablets 60 mg.
  • Strides Pharma unit receives USFDA approval for generic drug to treat gastrointestinal diseases.
  • Strides receives USFDA approval for Theophylline Extended-Release Tablets 300 mg and 450 mg.
  • Strides acquires balance stake in Strides Global Consumer Healthcare Limited, UK.
  • Strides receives USFDA approval for Sucralfate Oral Suspension 1gm/10 mL.
  • Strides receives USFDA approval for Sevelamer Carbonate Tablets 800 mg.
  • Strides receives USFDA approval for Fluoxetine Tablets 10 mg and 20 mg.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkSell578738938.6931 Oct 2025
GRAVITON RESEARCH CAPITAL LLPbulkBuy578738937.2231 Oct 2025
AUTHUM INVESTMENT & INFRASTRUCTURE LIMITEDbulkBuy518350558.8822 Jan 2025
AMANSA HOLDING PRIVATE LTD.blockBuy24080071309 Feb 2024
SHASUN LEASING & FINANCE PVT LTDblockSell33567271309 Feb 2024
AMANSA HOLDING PRIVATE LTD.bulkBuy114030171309 Feb 2024
AMANSA HOLDING PRIVATE LTD.blockBuy33567271309 Feb 2024
BAJAJ FINANCE LIMITEDblockSell56382971309 Feb 2024
AMANSA HOLDING PRIVATE LTD.blockBuy56382971309 Feb 2024
BAJAJ FINANCE LIMITEDblockSell24080071309 Feb 2024

Read More

Strides Pharma Science Ltd News

Strides Pharma gets three USFDA remarks at Alathur plant

Strides Pharma Science received three observations from the USFDA following an inspection of its Alathur facility, signalling a regulatory review of the manufacturing site.

12 Sept 2026

companies

Strides Pharma Q1FY26: Profit up 56% YoY

Strides Pharma Science reports consolidated net profit of ₹1,654.93 million for Q1FY26, driven by a ₹742.07 million gain from Pivot Path stake dilution. Revenue rose 13% YoY to ₹12,654 million.

31 Jul 2026

companies

Strides Pharma Science Q1 Earnings Call on July 31

Strides Pharma Science will host its Q1 earnings conference call on July 31 at 5 PM to discuss quarterly financial results.

24 Jul 2026

companies

Strides Pharma Science files BRSR for FY26

Strides Pharma Science filed its Business Responsibility & Sustainability Report for FY26 with exchanges. The report details ESG performance, including 44.19% renewable energy usage and zero fatalities.

21 Jul 2026

companies

Strides Pharma fixes July 31 record date

Strides Pharma Science Ltd set July 31, 2026 as the record date for a final dividend of ₹5 per share, pending shareholder approval at its AGM on August 14, 2026.

20 Jul 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Strides Pharma Science Ltd?

    As of 26/09/2026 at 2:35 AM, Strides Pharma Science Ltd shares are trading at ₹1223.10.

  • 2.What is the market cap. of Strides Pharma Science Ltd?

    As of 26/09/2026, the market capitalization of Strides Pharma Science Ltd is ₹11,245.07 crore.

  • 3.When was Strides Pharma Science Ltd founded?

    Strides Pharma Science Ltd was founded in 1990.

  • 4.What are the P/E and P/B ratios of Strides Pharma Science Ltd?

    As of 26/09/2026, Strides Pharma Science Ltd has a P/E ratio of 18.38 and a P/B ratio of 2.42.

  • 5.How can I buy shares of Strides Pharma Science Ltd?

    You can buy shares of Strides Pharma Science Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Strides Pharma Science Ltd?

    As of March,2026, promoters hold 27.91% in Strides Pharma Science Ltd, while FIIs, DIIs and public shareholders hold 28.68%, 14.45% and 28.95%, respectively. The government holds 0.01%.

  • 7.Does Strides Pharma Science Ltd pay dividends?

    Yes, Strides Pharma Science Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹Final Dividend - Rs. - 4 per share.

  • 8.What is the dividend yield of Strides Pharma Science Ltd?

    As of 26 September, 2026, the dividend yield of Strides Pharma Science Ltd stands at 0.41%.

  • 9.What are the latest financial results of Strides Pharma Science Ltd?

    For January,2024, Strides Pharma Science Ltd reported revenue of ₹4,475.00 crore and a net profit of ₹405.00 crore.

  • 10.What is the Stock symbol of Strides Pharma Science Ltd?

    STAR is the stock symbol of Strides Pharma Science Ltd.

  • 11.Who is the CEO of Strides Pharma Science Ltd?

    The CEO of Strides Pharma Science Ltd is Arun Kumar.